NCT05009823

Brief Summary

Severe acute malnutrition (SAM) is a life threatening condition and is defined by 1) a weight-for-height Z-score more than three standard deviations (SD) below the median based on the 2006 World Health Organization (WHO) growth standards, 2) a mid-upper arm circumference (MUAC) of less than 115 mm or 3) by the presence of nutritional edema. Signs such as edema, mucocutaneous changes, hepatomegaly, lethargy, anorexia, anemia, severe immune deficiency and rapid progression to mortality characterize a state commonly coined as "complicated SAM". Kwashiorkor is one of the forms of complicated SAM commonly distinguished by the unmistakable presence of bipedal edema. SAM results in high mortality rates of up to half a million child deaths annually. Undernourished children are at higher risk of mortality ranging from three-times more risk among children with moderate malnutrition to 10-times in SAM children compared to well-nourished children. Children with complicated SAM require inpatient treatment in specialized centers. The "Rehabilitation and Nutritional Education Center" (CREN) is a specialized center in Burkina Faso receiving on average 10 SAM children per day. Recovery rate is lower than international standards; and adverse events and mortality remain strikingly high. The main objective of this study is to assess the underlying risk factors affecting the effectiveness of the nutritional therapeutic treatment protocol for complicated SAM children under 5 years of age who have been referred to the CREN, at the Centre Hôspitalier Universitaire Souro, Bobo Dioulasso, Burkina Faso. The specific objective of this study is to better understand underlying risk factors associated with a lower recovery rate and high mortality in complicated SAM children referred to CREN for inpatient care. Risk factors associated with poor response to a standard dietary treatment at any phase will be assessed retrospectively.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,959

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 2, 2021

Completed
8 days until next milestone

Study Start

First participant enrolled

August 10, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 18, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

2.1 years

First QC Date

August 2, 2021

Last Update Submit

November 15, 2023

Conditions

Keywords

Severe acute malnutritionNutritional rehabilitationF75F100Ready to use therapeutic food (RUTF)Stabilization phaseTransition phaseKwashiorkorMarasmus

Outcome Measures

Primary Outcomes (5)

  • Number of days during the first phase of treatment

    Average number of days spent in the stabilization phase in Days

    Three to Seven days

  • Number of days during the transition phase of treatment

    Average number of days spent in the transition phase in Days

    Three to Five days

  • Daily weight gain during the first phase of treatment

    Average daily weight gain in the stabilization phase in Grams

    Three to Seven days

  • Daily weight gain during the transition phase

    Average daily weight gain in the transition phase in Grams

    Three to Five days

  • Edema redevelopment during the transition phase

    Edema redevelopment during the transition phase after starting to resolve during the stabilizing phase.

    Three to Five days

Secondary Outcomes (5)

  • Anorexia

    Through study completion, an average of 15 days

  • Mortality

    Through study completion, an average of 15 days

  • Diarrhea

    Through study completion, an average of 15 days

  • Vomiting

    Through study completion, an average of 15 days

  • Adherence to the dietary treatment

    Through study completion, an average of 15 days

Other Outcomes (7)

  • HIV/AIDS

    Through study completion, an average of 15 days

  • Hepatitis

    Through study completion, an average of 15 days

  • Tuberculosis

    Through study completion, an average of 15 days

  • +4 more other outcomes

Study Arms (2)

Stabilization phase

The dietetic treatment is given by the nurses every 2 hours on the first day; then if tolerance is good, every 3 hours the following days. No family meals during the stabilization phase. But the baby can breastfeed. A child will receive an antibiotic as per the national protocol, malaria treatment if diagnosed with malaria, Vitamin A if symptomatic eye damage, Folic acid in case of anemia, antifungal in case of candidiasis.

Dietary Supplement: Standard F75Dietary Supplement: Alternative F75 With CMVDietary Supplement: Alternative F75 Without CMV

Transition phase

The child is assigned to one the therapeutic regimen depending on the treatment received during the stabilization phase and the results of the appetite test.

Dietary Supplement: F100Dietary Supplement: Standard F75 + RUTFDietary Supplement: Alternative F75 with CMV + RUTFDietary Supplement: Alternative F75 without CMV + RUTF

Interventions

Standard F75DIETARY_SUPPLEMENT

F-75 contains 75 kcal and 0.9 g protein per 100 ml.

Stabilization phase
Alternative F75 With CMVDIETARY_SUPPLEMENT

Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.

Stabilization phase
Alternative F75 Without CMVDIETARY_SUPPLEMENT

Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.

Stabilization phase
F100DIETARY_SUPPLEMENT

100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)

Transition phase
Standard F75 + RUTFDIETARY_SUPPLEMENT

Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive

Transition phase

Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase

Transition phase

Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase

Transition phase

Eligibility Criteria

Age0 Months - 59 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Eligible participants are children 0-59 Months of age who were hospitalized in the pediatric department for SAM with or without edema, and children hospitalized in other departments from CHUSS and received at CREN for treatment of SAM.

You may qualify if:

  • Severe acute malnutrition defined as Weight-for-Height Z-score (WHZ) \<- 3 SD AND / OR MUAC \<115 mm AND / OR with edema
  • With complications
  • Who were admitted and treated in the refeeding center (CREN) of the CHUSS from January 2014 TO December 2018
  • Aged between 0 and 59 Months

You may not qualify if:

  • Older than 59 Months
  • Moderate Acute Malnutrition (MAM)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire Souro

Bobo-Dioulasso, Burkina Faso

Location

Related Publications (4)

  • Baraki AG, Akalu TY, Wolde HF, Takele WW, Mamo WN, Derseh B, Desyibelew HD, Dadi AF. Time to recovery from severe acute malnutrition and its predictors: a multicentre retrospective follow-up study in Amhara region, north-west Ethiopia. BMJ Open. 2020 Feb 13;10(2):e034583. doi: 10.1136/bmjopen-2019-034583.

    PMID: 32060161BACKGROUND
  • Bartz S, Mody A, Hornik C, Bain J, Muehlbauer M, Kiyimba T, Kiboneka E, Stevens R, Bartlett J, St Peter JV, Newgard CB, Freemark M. Severe acute malnutrition in childhood: hormonal and metabolic status at presentation, response to treatment, and predictors of mortality. J Clin Endocrinol Metab. 2014 Jun;99(6):2128-37. doi: 10.1210/jc.2013-4018. Epub 2014 Feb 27.

    PMID: 24606092BACKGROUND
  • Deen JL, Funk M, Guevara VC, Saloojee H, Doe JY, Palmer A, Weber MW. Implementation of WHO guidelines on management of severe malnutrition in hospitals in Africa. Bull World Health Organ. 2003;81(4):237-43. Epub 2003 May 16.

    PMID: 12764489BACKGROUND
  • Munthali T, Jacobs C, Sitali L, Dambe R, Michelo C. Mortality and morbidity patterns in under-five children with severe acute malnutrition (SAM) in Zambia: a five-year retrospective review of hospital-based records (2009-2013). Arch Public Health. 2015 May 1;73(1):23. doi: 10.1186/s13690-015-0072-1. eCollection 2015.

    PMID: 25937927BACKGROUND

Related Links

MeSH Terms

Conditions

Severe Acute MalnutritionKwashiorkorProtein-Energy Malnutrition

Condition Hierarchy (Ancestors)

MalnutritionNutrition DisordersNutritional and Metabolic DiseasesProtein DeficiencyDeficiency Diseases

Study Officials

  • Stefaan De Henauw, Md. PhD

    University Ghent

    PRINCIPAL INVESTIGATOR
  • Souheila Abbeddou, MSc. PhD

    University Ghent

    PRINCIPAL INVESTIGATOR
  • Jerome Some, Md. PhD

    Institut de Recherche en Sciences de la Sante, Burkina Faso

    PRINCIPAL INVESTIGATOR
  • Bintou Sanogo, MSc. Md.

    Centre Hospitalier Universitaire Souro, Bobo Dioulasso, Burkina Faso.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 2, 2021

First Posted

August 18, 2021

Study Start

August 10, 2021

Primary Completion

August 31, 2023

Study Completion

August 31, 2023

Last Updated

November 18, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

All the data that can affect the main or the secondary outcomes will be used in the analyses and shared as necessary.

Locations